Results 151 to 160 of about 15,263 (254)

Dupilumab Combined With House Dust Mite Allergen Immunotherapy for Atopic Dermatitis: A Systematic Review and Meta-Analysis. [PDF]

Clin Transl Allergy
Lian J, Ren L, Liang J, Guo S.
europepmc   +1 more source

Dupilumab treatment for pruritus-associated cutaneous sarcoidosis

Sarcoidosis is a chronic multisystemic, inflammatory disease characterized by the formation of noncaseating granulomas, with cutaneous involvement in a fraction of patients.
Pandher, Karan, Gao, David, Lim, Henry W, Choi, Sooin   +3 more
core  

Cardiovascular Outcomes With Dupilumab Versus Omalizumab in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Po‐Cheng Shih, Chun‐Ting Lin, James Cheng Chung Wei   +2 more
wiley   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis

International Journal of Dermatology, EarlyView.
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller, Helmut Beltraminelli, Wolf‐Henning Boehncke, Maximilian Böhm, Antonio Cozzio, Peter Häusermann, Ahmad Jalili, Antonios G. A. Kolios, Claudia Lang, Eva Loos, Christoph Schlapbach, Curdin Conrad   +11 more
wiley   +1 more source

Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis. [PDF]

Front Pharmacol
Khalifa MA, Ahmed Shimal A, Mahmoud MH, Roumi Jamal B, Atef P, Ali Ahmed MS, Khalil I, Alatise MB, Dway A, Irhayyif SR.   +9 more
europepmc   +1 more source

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications

Immunology, EarlyView.
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang, Fengyu Liu, Yongle Wei, Guoqiang Li, Liujie Zheng, Lin Jin, Feng Luan, Yingze Zhang, Ling Wang, Zhiyong Hou   +9 more
wiley   +1 more source

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz, Alain Hovnanian, Grace Xiong, Dedee Frances Murrell, Simon M. Mueller, Khaled Ezzedine, Nessa Aghazadeh Mohandesi, Ahmed Salem Aldhaheri, Nissim Asayag, Eulalia Baselga, Chen Nadler, Keith Choate, Chia‐Yu Chu, John Robert Edminister, Emmanuella Guenova, Melis Gönülal, Antoni Gostynski, Ankan Gupta, Lalit Kumar Gupta, Juliette Mazereeuw‐Hautier, Wolfram Hoetzenecker, Peter Itin, Marek Jankowski, Akiharu Kubo, Haur Yueh Lee, Julia Scott Lehman, Anfisa Lepekhova, Márta Medvecz, Jemima E. Mellerio, Verena Moosbrugger‐Martinz, Amy S. Paller, Dóra Plázár, Amadeu José Rodrigues Queiróz, Josep Riera‐Monroig, Ralph Rosa, Matthias Schmuth, Maella Severino Freire, Itzhak Shabat, Jonathan Shapiro, Cory L. Simpson, Diego Soto‐García, Alexander J. Stratigos, Gianluca Abel Tadini, Takuya Takeichi, Kaushal K. Verma, Jakob D. Wikström, Alexander Zink, Michael Ziv, Alexander Navarini, Roni Pircha Dodiuk‐Gad   +49 more
wiley   +1 more source

Clinical Characterization and Outcomes of Dupilumab for Pemphigoid Gestationis: A Case Series of Five Patients and Literature Review. [PDF]

Acta Derm Venereol
Meijer JM, Leeman EJ, Grabik D, Prens LM, Bouwman K, Prins JR, Gordijn SJ, Schoots MH, Bolling MC, Diercks GFH, Bremer J, Horváth B.   +11 more
europepmc   +1 more source

Dupilumab for the Treatment of Prurigo Nodularis

Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis driven by neural and immune dysregulation, with historically limited FDA-approved treatment options. In September 2022, dupilumab became the first FDA-approved therapy for PN.
Baker, Nicole, Alomary, Simona A., Encarnacion, Iain Noel, Desir, Noelle   +3 more
core